KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Interest & Investment Income (2016 - 2025)

Historic Interest & Investment Income for Inovio Pharmaceuticals (INO) over the last 11 years, with Q3 2025 value amounting to $552108.0.

  • Inovio Pharmaceuticals' Interest & Investment Income fell 5011.48% to $552108.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 5075.63%. This contributed to the annual value of $4.8 million for FY2024, which is 4138.91% down from last year.
  • As of Q3 2025, Inovio Pharmaceuticals' Interest & Investment Income stood at $552108.0, which was down 5011.48% from $610638.0 recorded in Q2 2025.
  • In the past 5 years, Inovio Pharmaceuticals' Interest & Investment Income registered a high of $1.9 million during Q3 2023, and its lowest value of $552108.0 during Q3 2025.
  • Over the past 3 years, Inovio Pharmaceuticals' median Interest & Investment Income value was $1.1 million (recorded in 2024), while the average stood at $1.2 million.
  • As far as peak fluctuations go, Inovio Pharmaceuticals' Interest & Investment Income tumbled by 4291.37% in 2024, and later plummeted by 5329.22% in 2025.
  • Quarter analysis of 3 years shows Inovio Pharmaceuticals' Interest & Investment Income stood at $1.8 million in 2023, then tumbled by 53.13% to $852587.0 in 2024, then crashed by 35.24% to $552108.0 in 2025.
  • Its Interest & Investment Income stands at $552108.0 for Q3 2025, versus $610638.0 for Q2 2025 and $808077.0 for Q1 2025.